Clinical and demographics characteristics | 5-year survival rate(%) | P value |
---|---|---|
Age | ||
<40 (n = 250) | 88.0 | |
≥40 (n = 22) | 72.7 | 0.13 |
Medical history of molar gestation | ||
Yes (n = 48) | 84.3 | |
No (n = 224) | 87.1 | 0.70 |
Interval from index pregnancy,month | ||
≤12 (n = 161) | 93.2 | |
>12 (n = 111) | 79.0 | 0.01 |
Pretreatment β-hCG,mIU/ml | ||
<100,000 (n = 220) | 84.9 | |
≥ 100,000 (n = 52) | 94.0 | 0.34 |
<400,000 (n = 257) | 86.3 | |
≥ 400,000 (n = 15) | 93.3 | 0.79 |
Metastatic sites | ||
1 (n = 195) | 91.0 | |
≥2 (n = 77) | 75.9 | 0.004 |
Abnormal uterine bleeding only | ||
Yes (n = 139) | 88.4 | |
No (n = 133) | 82.8 | 0.344 |
Fetal death or stillbirth | ||
Yes (n = 14) | 92.9 | |
No (n = 258) | 86.2 | 0.66 |
Resistance to multiagent chemotherapy | ||
Yes (n = 121) | 76.3 | |
No (n = 151) | 95.3 | 0.004 |
Brain metastasis | ||
Yes (n = 41) | 80.6 | |
No (n = 231) | 87.9 | 0.13 |
Kidney metastasis | ||
Yes (n = 6) | 83.3 | |
No (n = 266) | 86.7 | 0.55 |
Liver metastasis | ||
Yes (n = 10) | 33.3 | |
No (n = 262) | 89.0 | 0.000 |
Surgeries | ||
Yes (n = 141) | 85.5 | |
No (n = 131) | 87.4 | 0.25 |
FIGO score | ||
≤12 (n = 216) | 90.9 | |
>12 (n = 56) | 71.3 | 0.000 |